Perrone-Filardi Pasquale, Coca Antonio, Galderisi Maurizio, Paolillo Stefania, Alpendurada Francisco, de Simone Giovanni, Donal Erwan, Kahan Thomas, Mancia Giuseppe, Redon Josep, Schmieder Roland, Williams Bryan, Agabiti-Rosei Enrico
aDepartment of Advanced Biomedical Sciences, Federico II University of Naples, Naples, Italy bHypertension and Vascular Risk Unit, Department of Internal Medicine, Hospital Clínic (IDIBAPS), University of Barcelona, Barcelona, Spain cSDN IRCCS, Naples, Italy dNIHR Cardiovascular BRU, Royal Brompton & Harefield NHS Trust and Imperial College London, London, United Kingdom eHypertension Research Center (CIRIAPA), Federico II University of Naples, Naples, Italy fCardiology & Cic-it 1414, CHU Rennes LTSI, Insert 1099, Université Rennes-1, Rennes, France gDivision of Cardiovascular Medicine, Department of Clinical Sciences, Karolinska Institutet, Danderyd Hospital, Stockholm, Sweden hIRCCS Istituto Auxologico Italiano e Istituto Clinico Universitario di Verano Brianza, Policlinico di Monza, Monza, Italy iINCLIVA Research Institute, University of Valencia and CIBERObn Carlos III Institute, Madrid, Spain jDepartment of Nephrology and Hypertension, University Hospital Erlangen, Erlangen, Germany kUniversity College London and National Institute for Health Research University College London Hospitals Biomedical Research Centre, London, United Kingdom lDepartment of Clinical and Experimental Sciences, Clinica Medica, Hypertension and Cardiovascular Risk Research Centre, University of Brescia, Spedali Civili, Brescia, Italy.
J Hypertens. 2017 Sep;35(9):1727-1741. doi: 10.1097/HJH.0000000000001396.
: Arterial hypertension accounts for the largest amount of attributable cardiovascular mortality worldwide, and risk stratification in hypertensive patients is of crucial importance to manage treatment and prevent adverse events. Asymptomatic involvement of different organs in patients affected by hypertension represents an independent determinant of cardiovascular risk, and the identification of target organ damage is recommended to further reclassify patients' risk. Noninvasive cardiovascular imaging is progressively being used and continues to provide new technological opportunities to target organ damage evaluation at early stage. The aim of this article is to provide the community of cardiology with an update on appropriate and justified use of noninvasive imaging tests in the growing population of hypertensive patients.
动脉高血压是全球心血管疾病归因死亡的主要原因，高血压患者的风险分层对于治疗管理和预防不良事件至关重要。高血压患者不同器官的无症状受累是心血管风险的独立决定因素，建议识别靶器官损害以进一步重新分类患者风险。非侵入性心血管成像正逐渐得到应用，并继续为早期靶器官损害评估提供新的技术机会。本文旨在为心脏病学界提供最新信息，介绍在不断增加的高血压患者群体中合理使用非侵入性成像检查的情况。
